

An Open Label, 2 Year Long Term Follow-Up Study to Assess the Efficacy, Safety and Tolerability of Teneigliptin in Indian Subjects with Type 2 Diabetes Mellitus.

Rajnikanth B et al. International Annals of Medicine 2019; 3(1): 1-6.

- 47 patients to assess the efficacy, safety and tolerability of Teneigliptin 20 in patients with Type 2 diabetes.
- The total duration of study was 3 months after which the patients were followed up for 2 years. The Primary outcome was change in the HbA1C (%) from baseline to end of study and the secondary outcome included changes in FBG and 2 hr PPG from baseline at 1 month, 3 months and every quarterly till 24 months.
- There was a significant reduction in FBG and PPG after the end of 3 months as well as during the 2 year follow up, along with a reduction in HbA1C by 1.86% during the 2 year follow up.

Teneigliptin demonstrated the efficacy and safety as add-on treatment in achieving glycemic control in patients poorly controlled with glimepiride and metformin.